155 related articles for article (PubMed ID: 36653039)
1. Response to bipolar androgen therapy and PD-1 inhibition in a patient with metastatic castration-resistant prostate cancer and a germline
Berger BT; Labriola MK; Antonarakis ES; Armstrong AJ
BMJ Case Rep; 2023 Jan; 16(1):. PubMed ID: 36653039
[TBL] [Abstract][Full Text] [Related]
2. Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer.
Markowski MC; Shenderov E; Eisenberger MA; Kachhap S; Pardoll DM; Denmeade SR; Antonarakis ES
Prostate; 2020 Apr; 80(5):407-411. PubMed ID: 31972048
[TBL] [Abstract][Full Text] [Related]
3. Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer.
Annala M; Struss WJ; Warner EW; Beja K; Vandekerkhove G; Wong A; Khalaf D; Seppälä IL; So A; Lo G; Aggarwal R; Small EJ; Nykter M; Gleave ME; Chi KN; Wyatt AW
Eur Urol; 2017 Jul; 72(1):34-42. PubMed ID: 28259476
[TBL] [Abstract][Full Text] [Related]
4. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.
Teply BA; Wang H; Luber B; Sullivan R; Rifkind I; Bruns A; Spitz A; DeCarli M; Sinibaldi V; Pratz CF; Lu C; Silberstein JL; Luo J; Schweizer MT; Drake CG; Carducci MA; Paller CJ; Antonarakis ES; Eisenberger MA; Denmeade SR
Lancet Oncol; 2018 Jan; 19(1):76-86. PubMed ID: 29248236
[TBL] [Abstract][Full Text] [Related]
5. [Bipolar androgen therapy followed by immune checkpoint inhibitors in metastatic castration resistant prostate cancer: A report of 4 cases].
Liu SJ; Hou HM; Lv ZT; Ding X; Wang L; Zhang L; Liu M
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):766-769. PubMed ID: 35950406
[TBL] [Abstract][Full Text] [Related]
6. Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer.
Schweizer MT; Gulati R; Yezefski T; Cheng HH; Mostaghel E; Haffner MC; Patel RA; De Sarkar N; Ha G; Dumpit R; Woo B; Lin A; Panlasigui P; McDonald N; Lai M; Nega K; Hammond J; Grivas P; Hsieh A; Montgomery B; Nelson PS; Yu EY
Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):194-200. PubMed ID: 36564459
[TBL] [Abstract][Full Text] [Related]
7. Molecular and Clinical Characterization of Patients With Metastatic Castration Resistant Prostate Cancer Achieving Deep Responses to Bipolar Androgen Therapy.
Markowski MC; Kachhap S; De Marzo AM; Sena LA; Luo J; Denmeade SR; Antonarakis ES
Clin Genitourin Cancer; 2022 Apr; 20(2):97-101. PubMed ID: 34538582
[TBL] [Abstract][Full Text] [Related]
8. [Impact of germline BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-nave prostate cancer].
Matveev VB; Kirichek AA; Filippova MG; Savinkova AV; Khalmurzaev OA; Lyubchenko LN
Urologiia; 2019 Dec; (5):79-85. PubMed ID: 31808637
[TBL] [Abstract][Full Text] [Related]
9. Bipolar androgen therapy (BAT): A patient's guide.
Denmeade S; Antonarakis ES; Markowski MC
Prostate; 2022 May; 82(7):753-762. PubMed ID: 35357024
[TBL] [Abstract][Full Text] [Related]
10. The testosterone paradox of advanced prostate cancer: mechanistic insights and clinical implications.
Kumar R; Sena LA; Denmeade SR; Kachhap S
Nat Rev Urol; 2023 May; 20(5):265-278. PubMed ID: 36543976
[TBL] [Abstract][Full Text] [Related]
11. A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts.
Markowski MC; Wang H; Sullivan R; Rifkind I; Sinibaldi V; Schweizer MT; Teply BA; Ngomba N; Fu W; Carducci MA; Paller CJ; Marshall CH; Eisenberger MA; Luo J; Antonarakis ES; Denmeade SR
Eur Urol; 2021 May; 79(5):692-699. PubMed ID: 32624280
[TBL] [Abstract][Full Text] [Related]
12. Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study.
Schweizer MT; Wang H; Luber B; Nadal R; Spitz A; Rosen DM; Cao H; Antonarakis ES; Eisenberger MA; Carducci MA; Paller C; Denmeade SR
Prostate; 2016 Sep; 76(13):1218-26. PubMed ID: 27338150
[TBL] [Abstract][Full Text] [Related]
13. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
14. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
[TBL] [Abstract][Full Text] [Related]
15. Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study.
Schweizer MT; Antonarakis ES; Wang H; Ajiboye AS; Spitz A; Cao H; Luo J; Haffner MC; Yegnasubramanian S; Carducci MA; Eisenberger MA; Isaacs JT; Denmeade SR
Sci Transl Med; 2015 Jan; 7(269):269ra2. PubMed ID: 25568070
[TBL] [Abstract][Full Text] [Related]
16. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
Kohli M; Tan W; Zheng T; Wang A; Montesinos C; Wong C; Du P; Jia S; Yadav S; Horvath LG; Mahon KL; Kwan EM; Fettke H; Yu J; Azad AA
EBioMedicine; 2020 Apr; 54():102728. PubMed ID: 32268276
[TBL] [Abstract][Full Text] [Related]
17. Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report.
Ma Y; He L; Huang Q; Zheng S; Zhang Z; Li H; Liu S
BMC Med Genet; 2018 Oct; 19(1):185. PubMed ID: 30333000
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific Antigen Kinetics During Androgen-deprivation Therapy Predict Response to Enzalutamide in Metastatic Castration-resistant Prostate Cancer.
Nagata Y; Matsukawa T; Tomisaki I; Fujimoto N
Anticancer Res; 2023 Jan; 43(1):429-436. PubMed ID: 36585210
[TBL] [Abstract][Full Text] [Related]
19. [Bipolar androgen therapy: A novel therapeutic strategy for castration-resistant prostate cancer].
Hu YH; Guo JC; Zhang M
Zhonghua Nan Ke Xue; 2017 Dec; 23(12):1138-1140. PubMed ID: 29738189
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study.
Kobayashi K; Okuno N; Arai G; Nakatsu H; Maniwa A; Kamiya N; Satoh T; Kikukawa H; Nasu Y; Uemura H; Nakashima T; Mikami K; Iinuma M; Tanabe K; Furukawa J; Kobayashi H
Jpn J Clin Oncol; 2021 Apr; 51(4):544-551. PubMed ID: 33324967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
